Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy
Portfolio Pulse from
Alterity Therapeutics has completed the last patient visit in its Phase 2 clinical trial for ATH434, a drug candidate targeting multiple system atrophy. Topline data is expected in early 2025.
December 04, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Alterity Therapeutics has completed the last patient visit in its Phase 2 trial for ATH434, targeting multiple system atrophy. Topline results are anticipated in early 2025, which could impact the stock price based on the trial's outcome.
The completion of the Phase 2 trial is a significant milestone for Alterity Therapeutics. The anticipation of topline results in early 2025 could lead to stock price volatility depending on the outcome. However, as the results are not yet available, the immediate impact on the stock price is neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100